Metastasierter Brustkrebs (Hormonrezeptor-positiv, HER2-negativ): Aktuelle Studienergebnisse

At the world's largest cancer congress, numerous studies on metastatic breast cancer were presented again in 2024. In this article, Prof. Dr. Nadia Harbeck from the LMU University Hospital Munich and Eva Schumacher-Wulf, editor-in-chief of Mamma Mia! The Breast Cancer Magazine, discuss: the postMONARCH study: What happens when the combination of CDK4/6 inhibitor and anti-hormone therapy is no longer effective? the 5-year update on the YoungPEARL study and the INAVO120 study, a pivotal trial for patients with a PIK3CA mutation This ASCO 2024 coverage is a collaboration between patients today (https://patientstoday.de/) and our partners AstraZeneca and Daiichi-Sankyo. More information is available at https://mammamia-online.de